Chronic kidney disease

Also called CKD

There are 4,252 papers on chronic kidney disease in aging research: 203 trials and 2,586 observational studies in people, 161 in animals, 9 in cells, 1,130 reviews.

Disease

4,252 papers study it1,598 more mention it1,546 findings

635 new papers in 30 daysSee all 5,850 papers on chronic kidney disease

At a glance

Chronic kidney disease is linked with higher mortality, stroke risk and functional decline in human cohorts. In people with heart failure, it is associated with frailty; in people with hypertension but no diabetes or prior stroke, it is linked with cognitive impairment and dementia. Other observational studies link kidney disease with older age, metabolic burden and inflammatory markers.

1,546 findings in 1,076 papers from 2008 to 2026, 263 of them since April 2026

“AAMR increased significantly from 132.0 in 1999 to 216.6 in 2020.”
Trends in chronic kidney disease-related mortality in older adults in the United States from 1999 to 2020: a cross-sectional studyAnnals of medicine and surgery (2012)2025doi:10.1097/ms9.0000000000003822
  • Human trial203
  • Humans2,586
  • Animals161
  • Cells9
  • In silico120

Interventions

14

SGLT2 inhibitors

downin humans4

4 studies
  1. SGLT2 inhibitors decrease chronic kidney disease in humans across diabetic and non-diabetic populations.

    “Landmark clinical trials have consistently demonstrated reductions in heart failure hospitalization, chronic kidney disease progression, and cardiovascular mortality across diabetic and non-diabetic populations.”

    Reviewacross diabetic and non-diabetic populations

    Cardiorenal Syndrome Reimagined: From Hemodynamic Failure to a Multisystem Cardio-Renal-Metabolic-Inflammatory Network in the SGLT2 Era

    Cardiology in review

  2. SGLT2 inhibitors decrease chronic kidney disease in humans (including in patients without diabetes).

    “Randomized trials and meta-analyses show their most consistent benefits are reducing heart failure hospitalization and slowing chronic kidney disease progression, including in patients without diabetes.”

    Reviewincluding in patients without diabetes

    SGLT2 Inhibitors in the Modern Cardiology Era: Mechanisms, Outcomes, and Clinical Applications

    Cardiology in review

  3. SGLT2 inhibitors decrease chronic kidney disease in type 2 diabetes, heart failure, and chronic kidney disease.

    “adding SGLT2 inhibitors to RAAS-based therapy reduces heart failure hospitalizations and slows kidney disease progression”

    Reviewin type 2 diabetes, heart failure, and chronic kidney disease

    Dual Inhibition of the Renin-Angiotensin-Aldosterone System and Sodium-Glucose Cotransporter-2: Mechanistic and Clinical Evidence for Cardiorenal Protection

    Biomedicines

  4. SGLT2 inhibitors protect against chronic kidney disease in people with and without diabetes.

    “SGLT2 inhibitors have offered protection against heart failure and chronic kidney disease”

    Reviewin people with and without diabetes

    Cardiorenal effects of therapies for type 2 diabetes and obesity

    The British journal of cardiology

More on SGLT2 inhibitors

GLP-1 receptor agonists

no changein humans1downin humans1HR 1.26

2 studies
  1. GLP-1 receptor agonists were not clearly linked with chronic kidney disease in humans (propensity-matched comparison with non-GLP-1 users) (HR 1.26 (95% CI 0.82-1.95)).

    “or progression to CKD between the two groups (HR 1.26, 95% CI 0.82-1.95; P = 0.294)”

    Humanspropensity-matched comparison with non-GLP-1 users12 monthsn = 1,391

    Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis

    Orphanet journal of rare diseases

  2. GLP-1 receptor agonists protect against chronic kidney disease in humans.

    “improving cardiovascular outcomes, and preserving renal function”

    Review

    Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists

    Reviews in cardiovascular medicine

More on GLP-1 receptor agonists

Aspirin

no changein humans1

1 study
  1. Aspirin was not clearly linked with chronic kidney disease in humans (Postpartum; aspirin prescription before 16 weeks of gestation).

    “No significant associations were observed for incident chronic kidney disease or cardiometabolic morbidity.”

    HumansPostpartum; aspirin prescription before 16 weeks of gestationMedian 5-year follow-upfemalesn = 31,042

    Association between aspirin use before 16 weeks of gestation and early postpartum cardiometabolic risk: an electronic health record–based study

    ESC Congress 2026 abstract

More on Aspirin

Physical inactivity

no changein humans1HR 1.22

1 study
  1. Physical inactivity was not clearly linked with chronic kidney disease in humans (without depressive symptoms vs physically active without depressive symptoms) (HR 1.22, 95% CI 0.82-1.83).

    “1.22 (95% CI: 0.82, 1.83) for physical inactivity without depressive symptoms”

    Humanswithout depressive symptoms vs physically active without depressive symptoms

    Joint effects of physical activity and depressive symptoms on chronic kidney disease risk: Findings from the CHARLS cohort

    Acta psychologica

More on Physical inactivity

Ras inhibitors

downin humans1

1 study
  1. Ras inhibitors decrease chronic kidney disease in four-pillar pharmacotherapy.

    “When tailored to the degree of albuminuria and eGFR, this treatment significantly slows the progression of chronic kidney disease and reduces cardiovascular risk.”

    Reviewin four-pillar pharmacotherapykidney

    Albuminuria for detection of chronic kidney disease: biomarker and therapeutic target

    Orvosi hetilap

More on Ras inhibitors

Alcohol

no changein humans1

1 study
  1. Alcohol was not clearly linked with chronic kidney disease in humans (adjusted Cox proportional hazards models).

    “alcohol intake was not associated with CKD incidence”

    Humansadjusted Cox proportional hazards modelsmean 11.7-year follow-upn = 5,369

    Association of ALDH2 rs671 Polymorphism with chronic kidney disease incidence in a population-based Korean cohort

    Scientific reports

More on Alcohol

Angiotensin-converting enzyme inhibitors

downin humans1

1 study
  1. Angiotensin-converting enzyme inhibitors protect against chronic kidney disease in patients with stage 3 to 5 chronic kidney disease.

    “in patients with stage 3 to 5 chronic kidney disease, limited evidence suggests that ACEIs may confer superior renoprotective benefits.”

    Reviewin patients with stage 3 to 5 chronic kidney disease

    All in on ARBs: Is it time to fold the ACEIs?

    Canadian family physician Medecin de famille canadien

More on Angiotensin-converting enzyme inhibitors

Finerenone

downin humans1

1 study
  1. Finerenone decreases chronic kidney disease in humans (established diabetic chronic kidney disease).

    “Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has also been shown to reduce kidney disease progression and cardiovascular events in patients with established diabetic CKD”

    Reviewestablished diabetic chronic kidney disease

    Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions

    Kidney research and clinical practice

More on Finerenone

Semaglutide

downin reviews1

1 study
  1. Semaglutide prevents chronic kidney disease (patients with type 2 diabetes).

    “In patients with type 2 diabetes, semaglutide prevents chronic kidney disease (CKD)”

    Reviewpatients with type 2 diabetes

    Nephrology : what's new in 2025

    Revue medicale suisse

More on Semaglutide

Dash diet

downin humans1

1 study
  1. Dash diet protects against chronic kidney disease in humans (CKD prevention and protection).

    “both MD and DASH exert significant preventive and protective effects against CKD”

    ReviewCKD prevention and protection

    New developments in epidemiological research on dietary patterns associated with chronic kidney disease

    Frontiers in nutrition

More on Dash diet

All 14

Effects

49

Mortality

upin humans6mediatesin humans1no changein humans1+25%OR 1.54

8 studies
  1. Chronic kidney disease is linked with mortality in humans (indirect effect mediating sex-related difference in TR-associated mortality) (indirect OR 1.54).

    “most prominent indirect effects related to chronic kidney disease (CKD; indirect OR 1.54)”

    Humansindirect effect mediating sex-related difference in TR-associated mortalityn = 122,501

    Sex, comorbidities, and mortality in tricuspid regurgitation: Reassessing risk beyond valve severity

    ESC Congress 2026 abstract

  2. Chronic kidney disease is linked with higher mortality in humans (+24.6%).

    “age-standardized mortality rate increased by 24.6% to 18.5 per 100,000”

    Humans

    Burden of chronic kidney disease and its attributable risk factors in 204 countries and territories, 1990-2021: Results from the Global Burden of Disease study 2021

    Medicine

  3. Chronic kidney disease is linked with higher mortality in 2021 (64.03 per 100,000).

    “Nearly two-thirds of patients were postmenopausal women, and their age-standardized mortality rate and age-standardized disability-adjusted life-years (DALYs) rate had significantly increased to 64.03 and 1493.31 per 100,000, respectively.”

    Humansin 2021females

    Chronic kidney disease in women: Global trends and metabolic-cardiovascular associations

    Chinese medical journal

  4. Chronic kidney disease is linked with higher mortality in humans with CKD (APC, 2.3 [95% CI, 1.7-3.0]).

    “mortality rates increased among women with CKD (APC, 2.3 [95% CI, 1.7-3.0]).”

    Humanswith CKDfemales

    National All-Cause Mortality Trends Among Adults With and Without CKD in the United States, 1999-2019

    American journal of kidney diseases : the official journal of the National Kidney Foundation

  5. Chronic kidney disease is linked with higher mortality in patients with chronic heart failure (2.5-fold (28.6% vs. 11.1%)).

    “In-hospital mortality was 2.5-fold higher in patients with CKD (28.6% vs. 11.1%; p < 0.001).”

    Humansin patients with chronic heart failuren = 2,227

    Impact of Chronic Kidney Disease on Clinical, Laboratory, and Echocardiographic Features in Patients with Chronic Heart Failure

    Diseases (Basel, Switzerland)

  6. Chronic kidney disease is linked with higher mortality in humans (coexisting CKD and dementia) (1.03 to 5.92 per 100 000 (AAPC 7.41%)).

    “The overall AAMR increased from 1.03 to 5.92 per 100 000 (AAPC 7.41%).”

    Humanscoexisting CKD and dementia1999 to 2020n = 170,375

    Mortality trends for chronic kidney disease and dementia in the United States, 1999-2020: a 22-year retrospective analysis

    Annals of medicine and surgery (2012)

  7. Chronic kidney disease was not clearly linked with mortality in humans (fragility fractures, eGFR 45-59 ml/min/1.73 m2) (HR 1.01, 95% CI 0.64-1.58).

    “but not in the 45-59 ml/min/1.73 m2 group (HR 1.01, 95% CI 0.64-1.58).”

    Humansfragility fractures, eGFR 45-59 ml/min/1.73 m2n = 453

    Chronic kidney disease and mortality in fragility fracture patients: revisiting GFR thresholds

    European geriatric medicine

  8. Chronic kidney disease increases mortality in humans (1.5 million annually).

    “1.5 million people annually (one every 20 seconds) die from CKD.”

    Review

    The updated global burden of chronic kidney disease: one death every 20 seconds

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Physical function

downin humans3

3 studies
  1. Chronic kidney disease is linked with worse physical function in humans (CKD stage 3 and 4 compared with healthy controls).

    “SPPB, MVIC, and 6MWT performance decreased significantly between HC to CKD stage 3, to CKD stage 4.”

    HumansCKD stage 3 and 4 compared with healthy controls

    Muscle strength, neuromuscular function, and functional measures across stages of chronic kidney disease

    BMC nephrology

  2. Chronic kidney disease is linked with worse physical function in patients with chronic heart failure (p < 0.001).

    “A significant difference in the distribution of NYHA functional classes was observed between the groups (p < 0.001), with NYHA class IV being more prevalent in the CKD group”

    Humansin patients with chronic heart failuren = 2,227

    Impact of Chronic Kidney Disease on Clinical, Laboratory, and Echocardiographic Features in Patients with Chronic Heart Failure

    Diseases (Basel, Switzerland)

  3. Chronic kidney disease is linked with worse physical function in humans (431.2 ± 112.9 vs. 484.1 ± 99.4 m).

    “poorer endurance (6MWT: 431.2 ± 112.9 vs. 484.1 ± 99.4 m)”

    Humansmales

    The Role of Brain Structure in Explaining Physical Functioning in Male Veterans With Impaired Kidney Function

    Journal of the American Geriatrics Society

Cellular senescence

upin humans1upin rats1

2 studies
  1. Chronic kidney disease increases cellular senescence in rats.

    “A marker of cellular senescence was elevated in cortical osteocytes due to both CKD and aging.”

    Animalscortical osteocytes

    Older rats had more severe bone changes with kidney disease

    Bone

  2. Chronic kidney disease induces cellular senescence in humans.

    “Besides, CKD and its comorbid conditions can result in inflammation, oxidative stress, apoptosis, and necrosis, which stimulate premature senescence in multiple body organs.”

    Review

    Oxidative stress and renal biology: Unraveling the bidirectional link with aging and chronic kidney disease

    Eurasian Journal of Medicine and Oncology

More on Cellular senescence

Potent GLP-1-RA initiation

no changein humans1

1 study
  1. Chronic kidney disease was not clearly linked with potent GLP-1-RA initiation in humans (CKD stages I to IV) (aOR 0.97 (stages I and II), 0.98 (stages III and IV)).

    “Chronic kidney disease across stage I to IV was not associated with increased odds of initiation (aOR 0.97 for stage I and II; 0.98 for stage III and IV).”

    HumansCKD stages I to IV

    Utilization patterns of potent GLP-1-RA among patients with type 2 diabetes in clinical practice

    ESC Congress 2026 abstract

More on Potent GLP-1-RA initiation

Gross domestic product loss

upin silico1

1 study
  1. Chronic kidney disease increases gross domestic product loss in silico (INT $6.45 trillion (95% CI, INT $5.34–$7.37 trillion)).

    “The cumulative GDP loss attributable to CKD from 2025 to 2060 is projected to be INT $6.45 trillion (95% CI, INT $5.34–$7.37 trillion)”

    In silico2025–2060

    China faces $6.45 trillion kidney disease burden through 2060

    Research SquarePreprint

Prevalence

upin silico1

1 study
  1. Chronic kidney disease increases prevalence in silico.

    “Age-standardized incidence and mortality rates are projected to remain relatively stable, while prevalence increases substantially.”

    In silico2025–2060

    China faces $6.45 trillion kidney disease burden through 2060

    Research SquarePreprint

Frailty

upin humans1

1 study
  1. Chronic kidney disease increases frailty in humans.

    “Chronic kidney disease (CKD) is increasingly recognized as a model of accelerated biological aging, characterized by premature cardiovascular disease and frailty.”

    Review

    Vascular frailty: A new paradigm linking biological aging, gero-nephrology, and vascular medicine

    Ageing research reviews

aPWV

upin humans1

1 study
  1. Chronic kidney disease is linked with higher aPWV in humans (stage 3b-5 CKD or receiving dialysis).

    “aPWV was higher in the CKD group than in controls.”

    Humansstage 3b-5 CKD or receiving dialysis

    Arterial Stiffness and Geriatric Syndromes in Older Adults With Chronic Kidney Disease: A Cross-Sectional Study

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

More on aPWV

Variant allele fraction of CHIP-associated mutations

upin humans1

1 study
  1. Chronic kidney disease is linked with higher variant allele fraction of CHIP-associated mutations in humans among CHIP-positive participants, compared with healthy controls in the GENIE cohort (7.3% versus 4.4%; P = 0.02).

    “the median VAF of CHIP-associated mutations was significantly higher in participants within the KNOW-CKD cohort compared with healthy controls in the GENIE cohort (7.3% versus 4.4%; P = 0.02)”

    Humansamong CHIP-positive participants, compared with healthy controls in the GENIE cohort

    Clonal Hematopoiesis of Indeterminate Potential and Kidney Failure in CKD: An East Asian Cohort Study

    Clinical journal of the American Society of Nephrology : CJASN

More on Variant allele fraction of CHIP-associated mutations

Clonal hematopoiesis prevalence

upin humans1

1 study
  1. Chronic kidney disease is linked with higher clonal hematopoiesis prevalence in humans (compared with general population controls in the GENIE cohort) (17% versus 11%; P = 0.04).

    “The prevalence of CHIP was significantly higher in the KNOW-CKD cohort than in the GENIE cohort (17% versus 11%; P = 0.04).”

    Humanscompared with general population controls in the GENIE cohort

    Clonal Hematopoiesis of Indeterminate Potential and Kidney Failure in CKD: An East Asian Cohort Study

    Clinical journal of the American Society of Nephrology : CJASN

More on Clonal hematopoiesis prevalence

All 49

Upstream

37

C-reactive protein

mediatesin humans2

2 studies
  1. C-reactive protein is linked with chronic kidney disease in humans (Mediation proportions ≤9.0%, declining to 1.7% for ≥4 components).

    “PIV and CRP partially mediated this, but the proportions were small (≤9.0%) and declined with MetS burden (1.7% for ≥4).”

    Humansmediation of the association between cumulative metabolic syndrome burden and chronic kidney diseasen = 20,326

    Cumulative metabolic syndrome components, inflammation, and chronic kidney disease: associations, mediation pathways and joint effects

    Frontiers in endocrinology

  2. C-reactive protein is linked with chronic kidney disease in humans (effect of homocysteine on CKD risk) (15.04%).

    “C-reactive protein and erythrocyte sedimentation rate mediating 15.04% and 6.39% of the effect, respectively”

    Humanseffect of homocysteine on CKD risk

    Sex-Differentiated Threshold Effects of Homocysteine Levels on CKD Risk in Patients with Hypertension and Coronary Artery Disease

    Journal of inflammation research

More on C-reactive protein

Body mass index

mediatesin humans2

2 studies
  1. Body mass index is linked with chronic kidney disease in humans (mediating sulfur microbial diet and CKD) (23.13% of the association).

    “BMI explained 23.13% of the association.”

    Humansmediating sulfur microbial diet and CKD

    Higher consumption of sulfur microbial diet is associated with the increased risk of chronic kidney disease

    Frontiers in nutrition

  2. Body mass index is linked with chronic kidney disease in humans (association of hypothyroidism with incident chronic kidney disease, with obesity).

    “Body mass index and obesity partially mediated this effect.”

    Humansassociation of hypothyroidism with incident chronic kidney disease, with obesity

    Association between a history of hypothyroidism and incident chronic kidney disease and potential mediators: A cohort study with Mendelian randomization analysis

    The Journal of international medical research

More on Body mass index

Hypertension duration

no changein humans1

1 study
  1. hypertension duration showed no clear effect on chronic kidney disease in humans.

    “Also, we observed no evidence suggesting modification of hypertension duration on intensive SBP treatment effect on kidney events (P for interaction >0.05).”

    Human trialaverage follow‐up time 3.17 yearsn = 8,230

    Effect of Hypertension Duration on the Associations Between Intensive Blood Pressure Control and Cardiac, Vascular, and Kidney Organ Damage

    Journal of the American Heart Association

  2. hypertension duration showed no clear effect on chronic kidney disease in humans (hypertension) (P for interaction >0.05).

    “For kidney events, no treatment interaction effects or significant associations with hypertension duration were observed (P for interaction >0.05).”

    Human trialhypertension

    Effect of Hypertension Duration on the Associations Between Intensive Blood Pressure Control and Cardiac, Vascular, and Kidney Organ Damage

    Journal of the American Heart Association

Time

no changein humans1downin humans1OR 0.95

1 study
  1. time was not clearly linked with chronic kidney disease in humans among individuals with hypertension.

    “No decrease in chronic kidney disease was seen among individuals with hypertension.”

    Humansamong individuals with hypertension

    Decreasing Prevalence of Chronic Kidney Disease Among U.S. Adults With Diabetes, 1999-2018

    AJPM focus

  2. time is linked with lower chronic kidney disease in humans among individuals with diabetes (40.5% to 35.4% (OR 0.95, 95% CI 0.90-0.99)).

    “prevalence of chronic kidney disease among individuals with diabetes decreased from 40.5% to 35.4% over 20 years (p=0.02) with a decline of ∼5% during each 4-year period (OR=0.95, 95% CI=0.90, 0.99)”

    Humansamong individuals with diabetes20 yearsn = 7,320

    Decreasing Prevalence of Chronic Kidney Disease Among U.S. Adults With Diabetes, 1999-2018

    AJPM focus

Pan-immune-inflammation value

mediatesin humans1

1 study
  1. Pan-immune-inflammation value is linked with chronic kidney disease in humans (Mediation proportions ≤9.0%, declining to 1.7% for ≥4 components).

    “PIV and CRP partially mediated this, but the proportions were small (≤9.0%) and declined with MetS burden (1.7% for ≥4).”

    Humansmediation of the association between cumulative metabolic syndrome burden and chronic kidney diseasen = 20,326

    Cumulative metabolic syndrome components, inflammation, and chronic kidney disease: associations, mediation pathways and joint effects

    Frontiers in endocrinology

More on Pan-immune-inflammation value

Incident hypertension and/or diabetes mellitus

mediatesin humans1

1 study
  1. Incident hypertension and/or diabetes mellitus is linked with chronic kidney disease in humans (Indirect pathways all p<0.05).

    “incident HTN and/or DM mediated the relationship between noise and CKD (indirect pathways all p<0.05, Figure 1) across noise thresholds.”

    HumansPartial mediation of the association between transportation noise and chronic kidney diseaseNoise thresholds of >45, >50, and >55 dBA

    Transportation noise linked to new chronic kidney disease

    ESC Congress 2026 abstract

More on Incident hypertension and/or diabetes mellitus

Decreasing waist circumference trajectory

no changein humans1HR 0.83

1 study
  1. decreasing waist circumference trajectory was not clearly linked with chronic kidney disease in humans (compared with stable waist circumference trajectory) (adjusted HR 0.83, 95% CI 0.56-1.23).

    “whereas the decreasing trajectory was not (adjusted HR, 0.83; 95% CI, 0.56-1.23).”

    Humanscompared with stable waist circumference trajectorymedian follow-up of 11.8 yearsn = 5,429

    Association of waist circumference trajectories with incident chronic kidney disease

    Kidney research and clinical practice

Visceral adiposity index

no changein humans1OR 1.03

1 study
  1. Visceral adiposity index was not clearly linked with chronic kidney disease in humans (high dietary magnesium intake) (OR 1.03, 95% CI 0.96-1.10).

    “In contrast, no significant relation was observed among individuals with high dietary magnesium intake (OR = 1.03, 95% CI: 0.96-1.10; P = 0.252).”

    Humanshigh dietary magnesium intake

    Dietary magnesium intake modified association between visceral adiposity index and chronic kidney disease: a cross-sectional study

    Food & nutrition research

More on Visceral adiposity index

Excess adiposity

no changein humans1

1 study
  1. Excess adiposity was not clearly linked with chronic kidney disease in Korean adults with type 2 diabetes mellitus.

    “excess adiposity was associated with increased risk in women but not in men.”

    Humansin Korean adults with type 2 diabetes mellitus4 yearsmales

    Underweight is linked to higher kidney disease risk in diabetes

    Frontiers in endocrinology

INHBC

mediatesin silico1

1 study
  1. INHBC mediates chronic kidney disease in silico (association between T2D and kidney disease diagnosis) (1.3% (95% CI 0.85% to 1.9%)).

    “circulating INHBC levels mediate 1.3% (95% confidence interval [0.85%, 1.9%]) of the association between T2D and kidney disease diagnosis”

    In silicoassociation between T2D and kidney disease diagnosis

    Protein mediators of chronic kidney disease in Type 2 diabetes: A mendelian randomization study

    PLoS medicine

More on INHBC

All 37

Associations

479

Mortality

upin humans36no changein humans1mixedin humans1+57% mortalityHR 1.174–5.35

38 studies
  1. Chronic kidney disease is associated with mortality in humans (Exploratory analysis among individuals undergoing lower limb amputation).

    “Exploratory analyses identified chronic kidney disease and heart failure among the comorbidities associated with increased mortality.”

    HumansExploratory analysis among individuals undergoing lower limb amputation

    Mortality and survival rates following lower limb amputation: a national observational cohort study in Sweden

    Scientific reports

  2. Chronic kidney disease predicts mortality in humans Following ICD implantation (HR 1.81, 95% CI 1.41-2.34; mortality 3.1% in G1 versus 36.8% in G5/ESRD).

    “In multivariable analysis, CKD was the strongest independent predictor of mortality (HR 1.81, 95% CI 1.41-2.34, p<0.001)”

    HumansFollowing ICD implantationMedian follow-up 2,414 days37% femalesn = 1,662

    Chronic Kidney Disease Stage Predicts Long-Term Mortality Following ICD Implantation: Evidence from the All of Us Research Program

    AHA Scientific Sessions 2026 abstract

  3. Chronic kidney disease is linked with a higher risk of mortality in humans (patients with heart failure and metabolic syndrome; compared with eGFR ≥60) (41% excess mortality risk; adjusted HR 2.14 in eGFR <15).

    “CKD overall was associated with 41% excess mortality risk.”

    Humanspatients with heart failure and metabolic syndrome; compared with eGFR ≥60

    Chronic kidney disease in metabolic syndrome and heart failure: elevated risk, underutilized therapies, and missed opportunities for improved outcomes

    ESC Congress 2026 abstract

  4. Chronic kidney disease is associated with mortality in humans (Patients with NSTEMI; adjusted analysis of individual CKM components) (TAMI HR 1.466; MIMIC-IV HR 1.495).

    “Among the individual components, CKD was associated with the highest mortality risk in both cohorts (TAMI cohort HR: 1.466; MIMIC-IV cohort HR: 1.495)”

    HumansPatients with NSTEMI; adjusted analysis of individual CKM components10 years

    Prognostic impact of cardiovascular-kidney-metabolic overlap among patients with non-ST-segment elevation myocardial infarction: a multi-cohort study

    ESC Congress 2026 abstract

  5. Chronic kidney disease is associated with mortality in humans (Heart failure and metabolic syndrome; multivariable adjustment) (eGFR <60: HR 1.55 in men versus 1.62 in women; p-interaction=0.875).

    “After multivariable adjustment worsening CKD was similarly associated with mortality in men and women (eGFR <60: HR 1.55 vs 1.62; p-interaction=0.875).”

    HumansHeart failure and metabolic syndrome; multivariable adjustmentMedian follow-up 8.89 yearsn = 5,629

    Sex-specific impact of chronic kidney disease on mortality and dialysis in heart failure with metabolic syndrome

    ESC Congress 2026 abstract

  6. Chronic kidney disease predicts mortality in humans (HR 1.80, 95% CI 1.32–2.44).

    “CKD remained independently associated with mortality (HR 1.80, 95% CI 1.32–2.44).”

    Humansn = 2,376

    Interaction between creatinine and postoperative high-sensitivity troponin elevation for long-term mortality risk after non-cardiac surgery: a postoperative ICU cohort

    ESC Congress 2026 abstract

  7. Chronic kidney disease predicts mortality in humans Following surgery for traumatic subaxial cervical spinal cord injury.

    “Increasing age, male sex, diabetes, heart failure, and chronic kidney disease independently predicted mortality.”

    HumansFollowing surgery for traumatic subaxial cervical spinal cord injuryn = 5,477

    Age-stratified mortality following operative management of complete versus incomplete traumatic subaxial cervical spinal cord injury

    The journal of spinal cord medicine

  8. Chronic kidney disease is linked with a higher risk of mortality in tuberculosis patients aged < 65 years (adjusted risk ratio 3.78).

    “CKD was more strongly associated with mortality below 65 years than at older ages (adjusted risk ratio 3.78 versus 1.75; ratio of risk ratios 2.16, 95% confidence interval 1.67–2.79; P < 0.001).”

    Humansin tuberculosis patients aged < 65 years

    Pre-existing chronic kidney disease and mortality in younger patients with tuberculosis: a nationwide prospective cohort study

    Research SquarePreprint

  9. Chronic kidney disease is linked with a higher risk of mortality in people with diabetes.

    “Mortality declined in people with and without CKD but remained substantially higher among those with CKD.”

    Humansin people with diabetes

    Prevalence, Incidence and Mortality of Chronic Kidney Disease in Type 1 and Type 2 Diabetes-A Nationwide Danish Register-Based Cohort Study

    Diabetes, obesity & metabolism

  10. Chronic kidney disease is associated with mortality in humans (coexisting with lung cancer) (from 0.70 to 1.50 per 100,000 population).

    “The overall AAMR increased from 0.70 to 1.50 per 100,000 population, corresponding to an AAPC of 1.29% (95% CI, 0.52–2.20).”

    Humanscoexisting with lung cancer1999–2024n = 37,851

    Trends in Mortality Involving Coexisting Lung Cancer and Chronic Kidney Disease in the United States: A CDC WONDER Analysis, 1999–2024

    Research SquarePreprint

All 39

Hypertension

upin humans13upin dogs1OR 2.61–12.3

14 studies
  1. Chronic kidney disease is associated with hypertension in humans (Adults with versus without chronic kidney disease) (OR 4.46, 95% CI 4.30-4.62; prevalence 76.1% versus 41.7%).

    “All components were significantly more prevalent with CKD: hypertension (76.1% vs. 41.7%; OR 4.46, 95% CI 4.30-4.62)”

    HumansAdults with versus without chronic kidney diseasen = 327,671

    Cardiometabolic Multimorbidity in United States Adults with Chronic Kidney Disease: A Nationally Representative Cross-Sectional Study

    AHA Scientific Sessions 2026 abstract

  2. Hypertension is associated with chronic kidney disease in humans (tertiary care internal medicine outpatients) (OR 2.61, 95% CrI 1.96–3.54).

    “hypertension (OR 2.61, 95% CrI 1.96 to 3.54)”

    Humanstertiary care internal medicine outpatients

    Prevalence, risk factors and renoprotective treatment of chronic kidney disease among internal medicine outpatients at a Central European tertiary care centre: a cross-sectional study

    BMJ open

  3. Hypertension is linked with a higher risk of chronic kidney disease in humans (adjusted for age, race, and gender in class II and III obesity patients) (OR 12.3).

    “The odds ratio for CKD was 12.3 for hypertensives and 4.0 for diabetics, adjusted for age, race, and gender.”

    Humansadjusted for age, race, and gender in class II and III obesity patientsn = 202

    Hypertension, diabetes, and central obesity as risk factors for chronic kidney disease in class II and III obesity patients

    Nutrition (Burbank, Los Angeles County, Calif.)

  4. Hypertension is linked with a higher risk of chronic kidney disease in patients with type 2 diabetes mellitus (aOR: 1.37, 95% CI: 1.10, 1.70).

    “hypertension (aOR: 1.37, 95% CI: 1.10, 1.70)”

    Humansin patients with type 2 diabetes mellitus

    Chronic kidney disease in type 2 diabetes: Identifying key risk factors from Johor national diabetes registry study

    The Medical journal of Malaysia

  5. Hypertension is linked with a higher risk of chronic kidney disease in humans (globally).

    “high blood glucose, hypertension, and obesity were identified as the leading contributors to CKD-related DALYs globally”

    Humansglobally

    Burden of chronic kidney disease and its attributable risk factors in 204 countries and territories, 1990-2021: Results from the Global Burden of Disease study 2021

    Medicine

  6. Hypertension is associated with chronic kidney disease in humans (p = 0.001).

    “hypertension status (p = 0.001) were significantly associated with CKD.”

    Humansmalesn = 46,510

    Lifestyle Related Chronic Kidney Disease Among Young Adults of Productive Age In Indonesia: Analysis of The 2023 Indonesian Health Survey

    MEDICA (International Medical Scientific Journal)

  7. Hypertension is linked with a higher risk of chronic kidney disease in humans.

    “Males, older adults, and participants with hypertension or diabetes mellitus were at higher risks.”

    Humans

    Trends in 10th Revision of the International Classification of Diseases-Coded CKD Incidence Among Chinese Adults

    Kidney international reports

  8. Hypertension is linked with a higher risk of chronic kidney disease in humans (national survey) (aOR 2.41 (2.07-2.82)).

    “CKD prevalence was highest in northwest Iran, increased significantly with age, with a stronger association observed for low eGFR than albuminuria, and was associated with hypertension (aOR 2.41 (2.07-2.82))”

    Humansnational surveyn = 17,607

    Prevalence and risk factors of chronic kidney disease among Iranian adults with and without diabetes: a cross-sectional study using STEPS 2021 national survey

    BMJ open

  9. Hypertension is associated with chronic kidney disease in clinic-based cohort in Sudan (14.3% exhibited GFR <60 mL/min/1.73 m2).

    “Hypertension was detected in 8.2% of the subjects, among whom 14.3% exhibited a glomerular filtration rate (GFR) of <60 mL/min/1.73 m2.”

    Humansin clinic-based cohort in Sudan

    Common Risk Factors Associated With Chronic Kidney Disease in Sudan: A Pilot Study

    Cureus

  10. Hypertension is associated with chronic kidney disease in humans (tribal communities).

    “CKD was positively associated with older age, hypertension, diabetes, lower education, and low body mass index (BMI).”

    Humanstribal communitiesn = 2,029

    CKD in Indigenous Populations in Kerala, India

    Kidney international reports

All 14

More on Hypertension

Diabetes mellitus

upin humans9OR 3.03–4

9 studies
  1. Diabetes mellitus is associated with chronic kidney disease in humans (Fulni-ô Indigenous adults; multivariable adjustment) (adjusted OR 3.03; 95% CI 1.53–5.90).

    “only age ≥ 60 years (adjusted OR 3.58; 95% CI 2.03–6.27) and diabetes (adjusted OR 3.03; 95% CI 1.53–5.90) remained independently associated with the composite outcome.”

    HumansFulni-ô Indigenous adults; multivariable adjustmentn = 569

    Prevalence and factors associated with chronic kidney disease among Fulni-ô Indigenous adults in Brazil

    BMC nephrology

  2. Diabetes mellitus is linked with a higher risk of chronic kidney disease in humans (adjusted for age, race, and gender in class II and III obesity patients) (OR 4.0).

    “The odds ratio for CKD was 12.3 for hypertensives and 4.0 for diabetics, adjusted for age, race, and gender.”

    Humansadjusted for age, race, and gender in class II and III obesity patientsn = 202

    Hypertension, diabetes, and central obesity as risk factors for chronic kidney disease in class II and III obesity patients

    Nutrition (Burbank, Los Angeles County, Calif.)

  3. Diabetes mellitus is linked with a higher risk of chronic kidney disease in humans.

    “Males, older adults, and participants with hypertension or diabetes mellitus were at higher risks.”

    Humans

    Trends in 10th Revision of the International Classification of Diseases-Coded CKD Incidence Among Chinese Adults

    Kidney international reports

  4. Chronic kidney disease is associated with diabetes mellitus in adults with hypertension (AOR 1.74, 95% CI 1.42-2.14).

    “chronic renal disease (1.74, 1.42-2.14)”

    Humansin adults with hypertension

    Prevalence of diabetes/prediabetes and their associated risk factors among adults with hypertension from iran: a nationwide study

    Scientific reports

  5. Diabetes mellitus is associated with chronic kidney disease in clinic-based cohort in Sudan (22.2% showed GFR <60 mL/min/1.73 m2).

    “Among the 15.8% of diabetic individuals, 22.2% showed a GFR of <60 mL/min/1.73 m2.”

    Humansin clinic-based cohort in Sudan

    Common Risk Factors Associated With Chronic Kidney Disease in Sudan: A Pilot Study

    Cureus

  6. Diabetes mellitus is associated with chronic kidney disease in humans (tribal communities).

    “CKD was positively associated with older age, hypertension, diabetes, lower education, and low body mass index (BMI).”

    Humanstribal communitiesn = 2,029

    CKD in Indigenous Populations in Kerala, India

    Kidney international reports

  7. Diabetes mellitus is linked with a higher risk of chronic kidney disease in humans (hypertensive patients) (AHR 3.08, 95% CrI 2.01-9.54).

    “diabetes mellitus (AHR = 3.08; 95% CrI: 2.01-9.54), and proteinuria positivity (AHR = 2.85; 95% CrI: 1.48-5.55) were significant predictors of the incidence of CKD”

    Humanshypertensive patientsn = 408

    Incidence and predictors of chronic kidney disease among hypertensive patients in Ethiopia: A Bayesian multivariate joint model

    PloS one

  8. Diabetes mellitus is associated with chronic kidney disease in humans (Bangladesh).

    “identified several factors associated with CKD in Bangladesh, such as diabetes mellitus, hypertension, lower economic and educational status, older age, and high dietary salt intake.”

    ReviewBangladesh

    Prevalence, risk factors, comorbidities and awareness of chronic kidney disease in Bangladesh: a systematic review and meta-analysis

    Scientific reports

  9. Diabetes mellitus raises the risk of chronic kidney disease in humans.

    “The major causes of CKD include diabetes mellitus, hypertension, glomerulonephritis, and genetic or hereditary kidney disorders.”

    Review

    CHRONIC KIDNEY DISEASE: GLOBAL BURDEN, RISK FACTORS, AND THERAPEAUTIC PERSPECTIVES

    Indian Journal of Health Care Medical & Pharmacy Practice

More on Diabetes mellitus

Cardiovascular disease

upin humans9OR 1.5–2.04

9 studies
  1. Chronic kidney disease is linked with a higher risk of cardiovascular disease in humans (multivariable logistic regression) (aOR 5.0).

    “Independent correlates included CKD (aOR 5.0)”

    Humansmultivariable logistic regressionn = 307

    Risk Factors for Cardiovascular Disease in Community-Dwelling Older Adults: The Potential Role of Dual Screening for Chronic Kidney Disease and Sarcopenia

    medRxivPreprint

  2. Chronic kidney disease is associated with cardiovascular disease in humans (independent of age and sex, adults with uncontrolled hypertension) (adjusted OR 1.5 (1.1-1.9)).

    “have higher prevalence of any cardiovascular disease (CVD, 1.5 [1.1-1.9])”

    Humansindependent of age and sex, adults with uncontrolled hypertension

    Chronic kidney disease in US adults with uncontrolled hypertension: prevalence, characteristics, and mortality, an NHANES analysis

    AHA Scientific Sessions 2025 abstract

  3. Cardiovascular disease is linked with a higher risk of chronic kidney disease in humans (compared to the healthy heart type) (OR = 2.04, 95% CI: 1.61-2.57).

    “while the cardiovascular type increased by 104% (OR = 2.04, 95% CI: 1.61-2.57)”

    Humanscompared to the healthy heart type

    Cardiometabolic risk phenotypes and chronic kidney disease incidence in older adults: a nationwide longitudinal cohort study

    BMC public health

  4. Chronic kidney disease is associated with cardiovascular disease in humans.

    “In CKD, cardiovascular risk progressively increases as kidney function declines.”

    Review

    Treatment of Hypercholesterolemia in Chronic Kidney Disease: Rationale and Therapeutic Approaches from the Non-Dialysis Stage to Kidney Transplantation

    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia

  5. Chronic kidney disease raises the risk of cardiovascular disease in humans.

    “CKD is a key risk factor, mediator and therapeutic target to reduce CVD burden.”

    Review

    The therapeutic approach to cardiovascular-kidney-metabolic syndrome

    Nature reviews. Nephrology

  6. Chronic kidney disease raises the risk of cardiovascular disease in older adults.

    “Chronic kidney disease (CKD) is a progressive condition that increases the risk of cardiovascular disease, end-stage kidney disease and premature death.”

    Reviewin older adults

    Prevent chronic kidney disease and its complications in older adults with a stepwise approach

    Drugs & Therapy Perspectives

  7. Chronic kidney disease raises the risk of cardiovascular disease in chronic kidney disease.

    “Cardiovascular disease (CVD), which can manifest as coronary artery disease (CAD), stroke, heart failure (HF), arrhythmias, and sudden cardiac death, is more likely to develop in patients with chronic kidney disease (CKD).”

    Reviewin chronic kidney disease

    Current Appraisal and Gaps in Knowledge in Cardio-Kidney Metabolic Syndrome Definition

    International journal of molecular sciences

  8. Chronic kidney disease raises the risk of cardiovascular disease in humans.

    “people with CKD are more likely to die from CVD than progress to end-stage kidney disease.”

    Review

    Chronic kidney disease screening to reduce cardiovascular risk: a call to action

    American journal of preventive cardiology

  9. Chronic kidney disease raises the risk of cardiovascular disease in CKD.

    “Chronic kidney disease (CKD) substantially increases cardiovascular risk, with endothelial dysfunction as its central pathological mechanism.”

    Reviewin CKD

    Endothelial Dysfunction and Therapeutic Advances in Chronic Kidney Disease

    Diabetes/metabolism research and reviews

More on Cardiovascular disease

Frailty

upin humans8+57%OR 4.25

8 studies
  1. Chronic kidney disease is associated with frailty in humans (adults aged ≥ 40 years) (OR 4.25, 95% CI 1.62–11.10).

    “chronic kidney disease (4.25 [1.62;11.10]) were associated with frailty”

    Humansadults aged ≥ 40 yearsn = 5,296

    Multiple chronic illnesses common in adults at five African sites

    Research SquarePreprint

  2. Frailty is linked with a higher risk of chronic kidney disease in humans (HR 2.75 (95% CI: 2.61, 2.89)).

    “frailty compared to robust individuals were 1.64 (95% CI: 1.59, 1.69) and 2.75 (95% CI: 2.61, 2.89), respectively.”

    Humans

    Deficit accumulation frailty and risk of incident chronic kidney disease: a prospective analysis of the UK biobank and CHARLS cohorts

    International urology and nephrology

  3. Frailty is linked with a higher risk of chronic kidney disease in humans (multivariate model) (HR 1.606 (95% CI, 1.474-1.749, p < 0.001)).

    “Compared with non-frailty, the hazard ratio (HR) for new-onset CKD in prefrailty and frailty was 1.143 (95% CI, 1.090-1.199, p < 0.001) and 1.606 (95% CI, 1.474-1.749, p < 0.001)”

    Humansmultivariate modelmedian follow-up of 12.9 yearsn = 214,502

    Longitudinal Study of Frailty Phenotype in Relation to Chronic Kidney Disease Incidence

    Journal of cachexia, sarcopenia and muscle

  4. Chronic kidney disease is associated with frailty in humans (pre-dialysis chronic kidney disease) (57.07%).

    “Over half (57.07%) of the participants were rated as frail, with assignment to the frail group significantly influenced by age (p < .001) and CKD severity (p = .008).”

    Humanspre-dialysis chronic kidney diseasen = 191

    Frailty and Physical Function Performance of Elderly Outpatients With Pre-Dialysis Chronic Kidney Disease

    Hu li za zhi The journal of nursing

  5. Chronic kidney disease is associated with frailty in humans (15.2% in robust to 29.0% in frail (P < 0.001)).

    “The prevalence of chronic kidney disease (CKD) increased across frailty classes from 15.2% in robust to 29.0% in frail individuals (P < 0.001).”

    Humansn = 1,183

    The association between CKD and frailty in the FRASNET study: suggestion of a novel eGFR threshold as a key determinant of frailty in the elderly

    Journal of nephrology

  6. Chronic kidney disease is associated with frailty in humans (CKD stages G3-G5 by CKD-EPI) (>50%).

    “Over 50% of CKD patients fell into frail phenotypes (Senescent Nephropathy or Frailty Aged Kidney)”

    HumansCKD stages G3-G5 by CKD-EPIn = 58,611

    Reclassification of chronic kidney disease in the elderly: integrating age-adjusted GFR and frailty assessment in a regional Italian population (Abruzzo)

    International urology and nephrology

  7. Chronic kidney disease is associated with frailty in elderly patients.

    “elderly chronic kidney disease (CKD) patients have emerged as a distinct population at a high risk of renal fibrosis progression and poor prognosis.”

    Reviewin elderly patients

    Common mechanisms and intervention strategies for chronic kidney disease and frailty in older adults

    Chinese Journal of Geriatrics

  8. Chronic kidney disease is associated with frailty in humans (chronic kidney disease).

    “Frailty in chronic kidney disease (CKD) is increasingly recognized as a manifestation of accelerated biological aging, characterized by systemic impairments that extend beyond the musculoskeletal domain.”

    Reviewchronic kidney disease

    Organ Crosstalk in CKD-Associated Frailty: Mechanistic Insights, Translational Opportunities, and Clinical Implications

    Biological & pharmaceutical bulletin

Sarcopenia

upin humans8OR 2.52–4.51

8 studies
  1. Chronic kidney disease is associated with sarcopenia in humans (CKD stages 3–5) (OR = 2.520).

    “CKD stages 3-5 (OR = 2.520)”

    HumansCKD stages 3–5malesn = 172

    Gut microbiota dysbiosis and clinical correlates of sarcopenia in community-dwelling oldest-old men: a cross-sectional study

    BMC geriatrics

  2. Chronic kidney disease is associated with sarcopenia in humans (non-dialysis CKD stages G4-5 vs healthy controls) (21.7% vs. 5.8%; OR 4.51 [1.91-11.8]).

    “The prevalence of sarcopenia (21.7% vs. 5.8%; OR 4.51 [1.91-11.8]), osteoporosis (21.7% vs. 10.1%; OR 2.44 [1.25-4.99]), and osteosarcopenia (8.7% vs 1.4%; OR 6.44 [1.39-60.4]) were higher in patients with CKD compared to controls.”

    Humansnon-dialysis CKD stages G4-5 vs healthy controls

    High prevalence of sarcopenia, osteoporosis and osteosarcopenia in patients with chronic kidney disease compared with healthy controls

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

  3. Sarcopenia is linked with a higher risk of chronic kidney disease in humans (patients with MASLD) (aHR 1.41, 95% CI 1.12-1.77).

    “the adjusted hazard ratio (aHR) for incident CKD in participants with sarcopenia compared to those without was 1.41 (95% CI: 1.12-1.77)”

    Humanspatients with MASLDn = 19,867

    Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease

    The journal of nutrition, health & aging

  4. Chronic kidney disease is linked with a higher risk of sarcopenia in humans (P < 0.01).

    “Chronic kidney disease demonstrated a persistent and statistically significant association with elevated sarcopenia risk throughout the entire study period (P < 0.01).”

    Humans

    Association between chronic kidney disease and sarcopenia: a national cohort study and two-step Mendelian randomization analysis

    Archives of gerontology and geriatrics

  5. Chronic kidney disease is associated with sarcopenia in humans (highest in advanced stages and among patients receiving renal replacement therapy) (5–62 % prevalence).

    “Sarcopenia is reported in 5–62 % of patients with CKD, with the highest prevalence observed in advanced stages and among those receiving renal replacement therapy.”

    Reviewhighest in advanced stages and among patients receiving renal replacement therapy

    Sarcopenia in patients with kidney disease: controversial and unresolved issues in diagnosis and treatment

    Perm Medical Journal

  6. Chronic kidney disease raises the risk of sarcopenia in humans.

    “Chronic kidney disease (CKD) is a condition associated with accelerated aging that contributes to disturbances in nutritional and functional status, thereby predisposing patients, especially whose with end-stage kidney disease, to an increased risk of sarcopenia.”

    Review

    Common pathogenetic pathways in the development of sarcopenia in patients with chronic kidney disease and metabolic disorders

    Nephrology and Dialysis

  7. Chronic kidney disease is associated with sarcopenia in humans (chronic kidney disease).

    “A distinctive yet underappreciated feature of CKD-associated frailty is its triple burden-the co-existence of sarcopenia, bone fragility, and cognitive impairment.”

    Reviewchronic kidney disease

    Organ Crosstalk in CKD-Associated Frailty: Mechanistic Insights, Translational Opportunities, and Clinical Implications

    Biological & pharmaceutical bulletin

  8. Chronic kidney disease is associated with sarcopenia in CKD patients.

    “The prevalence of sarcopenia is significantly higher in CKD patients and increases as kidney function deteriorates.”

    Reviewin CKD patients

    Association between chronic kidney disease and sarcopenia and emerging treatment strategies

    Frontiers in nutrition

More on Sarcopenia

Metabolic dysfunction-associated steatotic liver disease

upin humans7HR 1.36–1.64

7 studies
  1. Metabolic dysfunction-associated steatotic liver disease is associated with chronic kidney disease in humans (HR 1.64, 95% CI 1.45–1.85).

    “and MASLD with incident CKD (HR = 1.64, 95% CI = 1.45-1.85; both P < 0.001)”

    Humansn = 438,126

    Kidney disease linked to metabolic fatty liver disease both ways

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  2. Chronic kidney disease is associated with metabolic dysfunction-associated steatotic liver disease in humans (HR 1.36, 95% CI 1.26–1.48).

    “CKD was associated with incident MASLD (HR = 1.36, 95% CI = 1.26-1.48)”

    Humansn = 462,516

    Kidney disease linked to metabolic fatty liver disease both ways

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  3. Metabolic dysfunction-associated steatotic liver disease is associated with chronic kidney disease in humans (OR 2.47 (95% CI 1.76-3.47)).

    “MASLD was associated with CKD (adjusted OR, 2.47; 95% CI, 1.76-3.47; p<0.001).”

    Humans

    Association of MASLD with chronic kidney disease according to metabolic profiles and fibrosis severity: a KNHANES analysis

    Frontiers in endocrinology

  4. Metabolic dysfunction-associated steatotic liver disease predicts chronic kidney disease in humans (FLI-defined lean MASLD).

    “FLI-defined lean MASLD, characterized by severe metabolic abnormalities, predicted a higher incident CKD risk”

    HumansFLI-defined lean MASLD

    Incident chronic kidney disease risk and the predictive value of the uric acid-to-HDL ratio in lean and non-lean MASLD: a prospective cohort and multi-omics study

    International urology and nephrology

  5. Metabolic dysfunction-associated steatotic liver disease is linked with a higher risk of chronic kidney disease in UK Biobank participants.

    “While non-lean MASLD consistently increased CKD risk”

    Humansin UK Biobank participants

    Incident chronic kidney disease risk and the predictive value of the uric acid-to-HDL ratio in lean and non-lean MASLD: a prospective cohort and multi-omics study

    International urology and nephrology

  6. Metabolic dysfunction-associated steatotic liver disease is associated with chronic kidney disease in humans (meta-analysis) (OR 1.19 [1.08-1.31]).

    “NAFLD: OR 1.19 [1.08-1.31], RR 1.66 [1.45-1.91], HR 1.43 [1.31-1.55]; MASLD: HR 1.34 [1.08-1.67]”

    Humansmeta-analysis

    The association between steatotic liver disease and chronic kidney disease: a meta-analysis and Mendelian randomization study highlighting metabolic comorbidities

    Nutrition & diabetes

  7. Metabolic dysfunction-associated steatotic liver disease raises the risk of chronic kidney disease in humans.

    “MASLD increases the risk of cardiovascular and renal complications mainly through shared mechanisms”

    Review

    MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome

    Science China. Life sciences

  8. Metabolic dysfunction-associated steatotic liver disease is associated with chronic kidney disease in humans.

    “The risk of developing CVD and CKD is considerably elevated in patients with MASLD.”

    Review

    The evolving concept from Cardiovascular-kidney-metabolic syndrome to metabolic associated liver-cardiovascular-kidney syndrome: insights from endocrinology

    Reviews in endocrine & metabolic disorders

  9. Metabolic dysfunction-associated steatotic liver disease raises the risk of chronic kidney disease in humans.

    “Studies consistently demonstrate a higher prevalence of CKD among patients with MASLD, with greater risk in those with advanced disease such as metabolic dysfunction-associated steatohepatitis and fibrosis.”

    Review

    The Metabolic Dysfunction-Associated Steatotic Liver Disease-CKD Axis: Intersecting Pathways and Opportunities for Early Intervention

    Kidney international reports

More on Metabolic dysfunction-associated steatotic liver disease

Obesity

upin humans7OR 1.46

7 studies
  1. Obesity is associated with chronic kidney disease in humans (Ghanaian clinic attendees) (aORs 7–8 for Obese I/II).

    “Obesity was the strongest independent predictor of CKD (aORs:7–8 for Obese I/II).”

    HumansGhanaian clinic attendeesn = 203

    Cardiometabolic multimorbidity and associated clinical, lifestyle and genetic factors among Ghanaian patients

    PloS one

  2. Chronic kidney disease is associated with obesity in humans (Adults with versus without chronic kidney disease; obesity defined as BMI ≥30 kg/m2) (OR 1.46, 95% CI 1.41-1.51; prevalence 42.1% versus 33.3%).

    “obesity (42.1% vs. 33.3%; OR 1.46, 95% CI 1.41-1.51; all p < 0.001)”

    HumansAdults with versus without chronic kidney disease; obesity defined as BMI ≥30 kg/m2n = 327,671

    Cardiometabolic Multimorbidity in United States Adults with Chronic Kidney Disease: A Nationally Representative Cross-Sectional Study

    AHA Scientific Sessions 2026 abstract

  3. Obesity is linked with a higher risk of chronic kidney disease in hypertensive patients (AHR 2.56, 95% CI 1.63-4.01).

    “obesity (AHR = 2.56, 95%CI: 1.63-4.01), and high triglyceride levels (AHR = 1.72, 95%CI: 1.03-2.91) were significant predictors of rapid progression of chronic kidney disease”

    Humansin hypertensive patients

    Chronic kidney disease progression rate and predictors in hypertensive patients: A 5-year retrospective follow-up study in Ethiopia

    PloS one

  4. Obesity is linked with a higher risk of chronic kidney disease in humans (national survey) (aOR 1.94 (1.59-2.36)).

    “obesity (1.94 (1.59-2.36))”

    Humansnational surveyn = 17,607

    Prevalence and risk factors of chronic kidney disease among Iranian adults with and without diabetes: a cross-sectional study using STEPS 2021 national survey

    BMJ open

  5. Obesity raises the risk of chronic kidney disease in humans.

    “Obesity is an important risk factor for chronic kidney disease (CKD)”

    Review

    Obesity and chronic kidney disease: a cardio-kidney-metabolic framework for renal vulnerability and risk stratification

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

  6. Obesity raises the risk of chronic kidney disease in humans.

    “Additional risk factors such as obesity, aging, cardiovascular diseases, and exposure to nephrotoxic agents further contribute to the growing burden of the disease.”

    Review

    CHRONIC KIDNEY DISEASE: GLOBAL BURDEN, RISK FACTORS, AND THERAPEAUTIC PERSPECTIVES

    Indian Journal of Health Care Medical & Pharmacy Practice

  7. Obesity raises the risk of chronic kidney disease in humans (chronic kidney disease).

    “Excess weight not only increases CKD risk but also heightens the risk for heart failure, sleep apnea, steatotic liver disease, osteoarthritis”

    Reviewchronic kidney disease

    Obesity in CKD: Core Curriculum 2026

    American journal of kidney diseases : the official journal of the National Kidney Foundation

More on Obesity

Type 2 diabetes

upin humans7OR 4.44

7 studies
  1. Chronic kidney disease is associated with type 2 diabetes in humans (Adults with versus without chronic kidney disease) (OR 4.44, 95% CI 4.30-4.59; prevalence 42.1% versus 14.1%).

    “T2DM (42.1% vs. 14.1%; OR 4.44, 95% CI 4.30-4.59)”

    HumansAdults with versus without chronic kidney diseasen = 327,671

    Cardiometabolic Multimorbidity in United States Adults with Chronic Kidney Disease: A Nationally Representative Cross-Sectional Study

    AHA Scientific Sessions 2026 abstract

  2. Type 2 diabetes is linked with a higher risk of chronic kidney disease in humans (type 2 diabetes mellitus) (aOR 1.80, 95% CI 1.40–2.31).

    “T2DM (aOR 1.80, 95% CI 1.40–2.31) were independently associated with CKD”

    Humanstype 2 diabetes mellitus

    Screening the silent epidemic: Community-based detection of chronic kidney disease in Vietnam’s elderly

    Aging Medicine and Healthcare

  3. Type 2 diabetes is linked with a higher risk of chronic kidney disease in people with overweight or obesity without CKD or HF at baseline (~2-3-fold).

    “Having T2D at baseline increased the 5-year risk of developing CKD by ~2-3-fold, and HF by ~1.5-fold.”

    Humansin people with overweight or obesity without CKD or HF at baseline5-year risk

    Risk of Developing Cardiorenal Complications in People Living with Overweight or Obesity, with vs. without T2D

    ADA Scientific Sessions 2026 abstract

  4. Type 2 diabetes is linked with a higher risk of chronic kidney disease in humans among individuals with hypertension (HR 2.944, 95% CI 2.760–3.139, P < 0.001).

    “those with coexisting type 2 diabetes (E11) had a significantly higher risk of developing CKD (N18) compared to those with atrial fibrillation (I48) or chronic ischaemic heart disease (I25) (HR = 2.944”

    Humansamong individuals with hypertension

    Uncovering core diseases in temporal trajectories of cardiovascular-kidney-metabolic (CKM) syndrome in UK Biobank: network-based study

    Scientific reports

  5. Type 2 diabetes is associated with chronic kidney disease in humans (Mendelian randomization).

    “genetically predicted metabolic factors-including body mass index (BMI), waist circumference, type 2 diabetes, systolic and diastolic blood pressure, triglycerides, and high-density lipoprotein cholesterol-were significantly associated with an increased CKD risk.”

    HumansMendelian randomization

    The association between steatotic liver disease and chronic kidney disease: a meta-analysis and Mendelian randomization study highlighting metabolic comorbidities

    Nutrition & diabetes

  6. Type 2 diabetes is linked with a higher risk of chronic kidney disease in humans (confirmed undiagnosed diabetes) (HR 1.33, 95% CI 1.02-1.73).

    “Confirmed undiagnosed diabetes was further associated with incident CKD (1.33 [1.02-1.73])”

    Humansconfirmed undiagnosed diabetesover 10 yearsn = 6,712

    Long-Term Health Outcomes in Individuals With Confirmed Versus Unconfirmed Undiagnosed Diabetes Based on Oral Glucose Tolerance Test: Findings From the Tehran Lipid and Glucose Study

    Journal of diabetes research

  7. Type 2 diabetes raises the risk of chronic kidney disease in humans (patients with type 2 diabetes).

    “Diabetes is also a major risk factor for chronic kidney disease, which in turn, is associated with an elevated risk of cardiovascular disease.”

    Reviewpatients with type 2 diabetes

    Why and how should the cardiovascular risk of patients with type 2 diabetes be assessed ?

    La Revue du praticien

More on Type 2 diabetes

Cellular senescence

upin reviews4upin humans2

6 studies
  1. Chronic kidney disease is associated with cellular senescence.

    “CKD is characterized by the presence of senescent tubular epithelial cells in increasing numbers in association with the injury of the nephrons”

    Reviewkidney

    Plant Extracellular Vesicle-Encapsulated Phytometabolites for Reversing Cellular Senescence Associated with Chronic Kidney Disease: A Mechanistic Review and Research Roadmap

    Natural Resources for Human Health

  2. Cellular senescence is associated with chronic kidney disease.

    “Cellular senescence, which represents a state of irreversible cell-cycle arrest accompanied by functional deterioration, is closely associated with AKI, CKD, and RCC.”

    Review

    Cellular Senescence in Kidney Diseases: From Bench to Clinic

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  3. Cellular senescence raises the risk of chronic kidney disease in humans.

    “Senescence predisposes not only to chronic diseases (including CKD) but also acute processes (including AKI).”

    Review

    The Aging Kidney and Acute Kidney Injury

    Journal of the American Society of Nephrology : JASN

  4. Cellular senescence raises the risk of chronic kidney disease.

    “inflammaging and cellular senescence contribute to chronic kidney disease (CKD) and impaired regeneration”

    Reviewkidney

    From Senescent Cells to Systemic Inflammation: The Role of Inflammaging in Age-Related Diseases and Kidney Dysfunction

    Cells

  5. Cellular senescence raises the risk of chronic kidney disease.

    “The bidirectional interplay between impaired autophagy and cellular senescence exacerbates renal tubular atrophy, glomerulosclerosis, and interstitial fibrosis, thereby promoting CKD progression and maladaptive repair following AKI.”

    Review

    Autophagy-senescence interplay in kidney disease: mechanistic insights and therapeutic potential

    Molecular biology reports

  6. Cellular senescence is associated with chronic kidney disease in humans.

    “age-related kidney disease, the counterpart of healthy aging kidney, is closely related to cellular and immune senescence”

    Review

    Healthy aging and aging-related kidney diseases: lessons from centenarians

    Clinical kidney journal

More on Cellular senescence

All 479

Trial sponsors

Funding

196 grants since 2016

National Institute of Diabetes and Digestive and Kidney Diseases$78.4MJapan Society for the Promotion of Science¥265MUS Department of Veterans Affairs

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    A human cohort links chronic kidney disease with worsening physical function and cognition; other observational studies associate it with higher mortality. In a heart-failure cohort, it is associated with incident frailty at age 70 or younger, but shows no clear link at 82 or older. Observational studies also link kidney disease with older age, diabetes, and metabolic syndrome.

  2. Summary rewritten as its findings changed.

    As it read before

    Accelerated biological aging is associated with higher chronic kidney disease risk in a human cohort; chronic kidney disease is also linked with functional decline and higher mortality. Human studies link it with dementia in people with diabetes or with hypertension without diabetes or prior stroke. In heart failure, its association with incident frailty varies by age, with no clear link at 82 or older.

  3. Summary rewritten as its findings changed.

    As it read before

    Human cohorts associate chronic kidney disease with functional decline, cognitive decline and higher mortality, and associate biological-age acceleration with subsequent chronic kidney disease. A study links sarcopenia to kidney disease in people with metabolic dysfunction-associated steatotic liver disease, while another associates moderate or vigorous physical activity with lower kidney disease risk in people with hypertension.

  4. Summary rewritten as its findings changed.

    As it read before

    Chronic kidney disease is associated with cognitive decline, dementia, and worsening functional limitations in human cohorts. Human studies also link it to biological-age acceleration, increased epigenetic age estimates in patients with CKD or end-stage renal disease, and senescent T cells in predialysis patients.

  5. Summary rewritten as its findings changed.

    As it read before

    Human cohorts associate chronic kidney disease with dementia in people with diabetes and mortality in patients hospitalized for heart failure. A preprint links it to frailty in adults aged 40 or older; human studies also associate older age and hypertension with chronic kidney disease.

Latest

See all 5,850 papers on chronic kidney disease